Novel therapeutic approach for NASH
NASH 的新治疗方法
基本信息
- 批准号:10616609
- 负责人:
- 金额:$ 51.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-04 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:2-arachidonylglycerolAdipose tissueAdverse effectsAgonistAmericanAnti-Inflammatory AgentsAntiinflammatory EffectAppetite StimulantsBehaviorBehavioralBindingBiological AssayBiological MarkersBrainCNR1 geneCNR2 geneCannabinoidsCatalepsyCellsCholesterolDevelopmentDietDiseaseDisparateDrug KineticsEarly identificationEndocannabinoidsEvaluationFatty LiverFatty acid glycerol estersGoalsHepaticHepatocyteHistologicImmuneIn VitroIndazolesInflammationLeadLigandsLipidsLiverLiver diseasesMarijuanaMetabolicMethionineModelingMusMuscleNeuronsNon-Insulin-Dependent Diabetes MellitusObesityOrganPET/CT scanPancreasPenetrationPeripheralPharmaceutical ChemistryPharmaceutical PreparationsPharmacologyPropertyPyrazolesReportingResearchSignal TransductionSkeletal MuscleTestingTetrahydrocannabinolTissuesUnited Statesanandamideantagonistantinociceptionbeta-arrestincannabinoid receptorcholine deficient dietclinical developmentdesignefficacy evaluationefficacy studyefficacy testingepidemiologic dataepidemiology studyfeedinginnovationislet amyloid polypeptideliver injuryliver transplantationmarijuana usemarijuana usernatural hypothermianonalcoholic steatohepatitisnovel strategiesnovel therapeutic interventionoverexpressionpharmacologicradioligandreceptorrecruitrelease of sequestered calcium ion into cytoplasmscaffoldside effectskeletal tissuesugar
项目摘要
The overall goal of this project is to develop peripherally restricted partial agonists of the cannabinoid receptors
(CB1 and CB2) for the treatment of non-alcoholic steatohepatitis (NASH). These compounds are expected to
mimic the peripheral effects of THC ((−)-trans-Δ⁹-tetrahydrocannabinol), the only known orthosteric ligand of
the CB receptors in marijuana while avoiding adverse CNS related side-effects. There are two known cannabinoid
receptors – CB1 and CB2. The CB1 receptor is highly expressed on neurons of the CNS along with certain
peripheral organs like the liver, pancreas, skeletal muscle and adipose tissue. The CB2 receptor is mostly
expressed on immune cells Epidemiological studies indicate that marijuana users have reduced rates of NASH,
type 2 diabetes and obesity. These contrarian effects are in sharp contrast to known orexigenic effects of
marijuana via the CNS. These observations can be explained by disparate pharmacological effects of THC – a
partial agonist. A partial agonist can act like a traditional agonist when excess receptors are present. However, a
partial agonist can also act as a functional antagonist when number of receptors is limited by competing with a
full agonist and by reducing downstream signaling. In the injured liver, the expression of CB1 is low to moderate
but there is a large influx of CB2 expressing immune cells. Further, expression of the full agonist
endocannabinoid 2-AG is ~1000-fold higher than that of the partial agonist AEA. We hypothesized that in NASH
a partial agonist might be able to reduce fatty liver via functional antagonism of CB1 while producing anti-
inflammatory effects by targeting CB2. We successfully tested this hypothesis using a well characterized partial
agonist of CB receptors and an early lead compound in a model of NASH. Continuation of our preliminary studies
is proposed through 3 integrated specific aims: (1) Synthesize partial CB receptor agonists that are peripherally
restricted. We have started to explore a primary indazole scaffold and a secondary pyrazole scaffold to produce
partial agonists of CB receptors that have limited CNS penetration. Continued refinement of early leads will lead
to compounds with optimized drug-like properties. (2) Perform pharmacological characterization using various
functional and binding assays and ADMET profiling of synthesized compounds to identify promising leads.
Select compounds will undergo pharmacokinetic evaluation and behavioral profiling to rule out CNS-effects. (3)
Perform efficacy testing in NASH models. We propose to evaluate our most promising leads in models of NASH
for efficacy. In tandem, we will assess various biomarkers of efficacy and perform receptor occupancy studies to
identify an optimized mature lead and two backups for further development.
该项目的总体目标是开发大麻素受体的外周限制性部分激动剂
(CB1和CB 2)用于治疗非酒精性脂肪性肝炎(NASH)。这些化合物预期
模拟THC((-)-反式-Δ ε-四氢大麻酚)的外周效应,THC是唯一已知的
大麻中的CB受体,同时避免不利的CNS相关副作用。有两种已知的大麻素
受体-CB 1和CB 2。CB 1受体在CNS的神经元上高度表达,沿着某些
外周器官如肝脏、胰腺、骨骼肌和脂肪组织。CB 2受体主要是
在免疫细胞上表达流行病学研究表明大麻使用者降低了NASH的发病率,
2型糖尿病和肥胖。这些相反的效果与已知的
大麻通过中枢神经系统这些观察结果可以用THC-a不同的药理作用来解释。
部分激动剂当存在过量受体时,部分激动剂可以像传统激动剂一样起作用。但
部分激动剂也可以作为功能性拮抗剂,当受体的数量受到限制时,
完全激动剂和减少下游信号传导。在损伤的肝脏中,CB 1的表达为低至中度
但有大量表达CB 2的免疫细胞流入。此外,完全激动剂的表达
内源性大麻素2-AG比部分激动剂AEA高约1000倍。我们假设在NASH中
部分激动剂可能能够通过CB 1的功能性拮抗作用减少脂肪肝,同时产生抗-
通过靶向CB 2的炎症作用。我们成功地测试了这一假设,使用一个良好的特点部分
CB受体激动剂和NASH模型中的早期先导化合物。继续我们的初步研究
通过3个整合的具体目标提出:(1)合成外周的部分CB受体激动剂,
限制。我们已经开始探索一级吲唑支架和二级吡唑支架,
CB受体的部分激动剂具有有限的CNS渗透。继续完善早期线索将导致
到具有优化的药物样性质的化合物。(2)使用各种药物进行药理学表征
合成化合物的功能和结合分析以及ADMET分析,以鉴定有希望的先导化合物。
选择的化合物将进行药代动力学评价和行为分析,以排除CNS效应。(三)
在NASH模型中进行有效性测试。我们建议在NASH模型中评估我们最有前途的线索
为了有效性。同时,我们将评估各种有效性生物标志物,并进行受体结合研究,
确定一个优化的成熟线索和两个备用线索,以便进一步开发。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Discovery of 1,3-disubstituted pyrazole peripheral cannabinoid receptor partial agonists.
1,3-二取代吡唑外周大麻素受体部分激动剂的发现。
- DOI:10.1016/j.bmcl.2023.129430
- 发表时间:2023
- 期刊:
- 影响因子:2.7
- 作者:Amato,George;Runyon,Scott;Vasukuttan,Vineetha;Decker,AnnM;Gay,ElaineA;Laudermilk,Lucas;Maitra,Rangan
- 通讯作者:Maitra,Rangan
Structure-Activity Relationship Development Efforts towards Peripherally Selective Analogs of the Cannabinoid Receptor Partial Agonist BAY 59-3074.
- DOI:10.3390/molecules27175672
- 发表时间:2022-09-02
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RANGAN MAITRA其他文献
RANGAN MAITRA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RANGAN MAITRA', 18)}}的其他基金
Conduct Confirmatory and Specialized In Vitro Testing and Screening of Interventional Agents in Standard Formats
以标准格式对介入药物进行验证性和专门的体外测试和筛选
- 批准号:
10925108 - 财政年份:2023
- 资助金额:
$ 51.8万 - 项目类别:
Conduct In Vitro Screening of Interventional Agents in High Throughput Screening (HTS) Formats: High Throughput Screening to Identify HIV Inhibitors
以高通量筛选 (HTS) 形式对介入药物进行体外筛选:通过高通量筛选识别 HIV 抑制剂
- 批准号:
10925107 - 财政年份:2023
- 资助金额:
$ 51.8万 - 项目类别:
Preclinical Services for HIV Therapeutics: QA/QC Plan and Task Order Initiation Meeting
HIV 治疗的临床前服务:QA/QC 计划和任务订单启动会议
- 批准号:
10397451 - 财政年份:2021
- 资助金额:
$ 51.8万 - 项目类别:
Investigation of Synthetic Cannabinoid Exposures and Pharmacological Consequences
合成大麻素暴露和药理学后果的调查
- 批准号:
10521643 - 财政年份:2016
- 资助金额:
$ 51.8万 - 项目类别:
Investigation of Synthetic Cannabinoid Exposures and Pharmacological Consequences
合成大麻素暴露和药理学后果的调查
- 批准号:
10704595 - 财政年份:2016
- 资助金额:
$ 51.8万 - 项目类别:
相似海外基金
Deciphering the role of adipose tissue in common metabolic disease via adipose tissue proteomics
通过脂肪组织蛋白质组学解读脂肪组织在常见代谢疾病中的作用
- 批准号:
MR/Y013891/1 - 财政年份:2024
- 资助金额:
$ 51.8万 - 项目类别:
Research Grant
ESTABLISHING THE ROLE OF ADIPOSE TISSUE INFLAMMATION IN THE REGULATION OF MUSCLE MASS IN OLDER PEOPLE
确定脂肪组织炎症在老年人肌肉质量调节中的作用
- 批准号:
BB/Y006542/1 - 财政年份:2024
- 资助金额:
$ 51.8万 - 项目类别:
Research Grant
Activation of human brown adipose tissue using food ingredients that enhance the bioavailability of nitric oxide
使用增强一氧化氮生物利用度的食品成分激活人体棕色脂肪组织
- 批准号:
23H03323 - 财政年份:2023
- 资助金额:
$ 51.8万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of new lung regeneration therapies by elucidating the lung regeneration mechanism of adipose tissue-derived stem cells
通过阐明脂肪组织干细胞的肺再生机制开发新的肺再生疗法
- 批准号:
23K08293 - 财政年份:2023
- 资助金额:
$ 51.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Canadian Alliance of Healthy Hearts and Minds: Dissecting the Pathways Linking Ectopic Adipose Tissue to Cognitive Dysfunction
加拿大健康心灵联盟:剖析异位脂肪组织与认知功能障碍之间的联系途径
- 批准号:
479570 - 财政年份:2023
- 资助金额:
$ 51.8万 - 项目类别:
Operating Grants
Determinants of Longitudinal Progression of Adipose Tissue Inflammation in Individuals at High-Risk for Type 2 Diabetes: Novel Insights from Metabolomic Profiling
2 型糖尿病高危个体脂肪组织炎症纵向进展的决定因素:代谢组学分析的新见解
- 批准号:
488898 - 财政年份:2023
- 资助金额:
$ 51.8万 - 项目类别:
Operating Grants
A study on the role of brown adipose tissue in the development and maintenance of skeletal muscles
棕色脂肪组织在骨骼肌发育和维持中作用的研究
- 批准号:
23K19922 - 财政年份:2023
- 资助金额:
$ 51.8万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
A mechanism of lipid accumulation in brown adipose tissue
棕色脂肪组织中脂质积累的机制
- 批准号:
10605981 - 财政年份:2023
- 资助金额:
$ 51.8万 - 项目类别:
Obesity and Childhood Asthma: The Role of Adipose Tissue
肥胖和儿童哮喘:脂肪组织的作用
- 批准号:
10813753 - 财政年份:2023
- 资助金额:
$ 51.8万 - 项目类别:
Estrogen Signaling in the Ventromedial Hypothalamus Modulates Adipose Tissue Metabolic Adaptation
下丘脑腹内侧区的雌激素信号调节脂肪组织代谢适应
- 批准号:
10604611 - 财政年份:2023
- 资助金额:
$ 51.8万 - 项目类别: